<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159840">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011594</url>
  </required_header>
  <id_info>
    <org_study_id>ZYTOP1407</org_study_id>
    <nct_id>NCT02011594</nct_id>
  </id_info>
  <brief_title>Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma</brief_title>
  <official_title>Phase II Study of Maintenance Treatment of Nimotuzumab Versus No Maintenance for Advanced Esophageal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is
      advantageous for advanced esophageal cancer patients in combination with chemotherapy or
      radiotherapy. However, whether maintenance therapy of nimotuzumab provides benefit to
      advanced esophageal cancer patients is not known.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We design this clinical trial to confirm the efficacy of maintenance treatment of
      nimotuzumab after initial treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PFS (Progression free survival)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stage IV Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nimotuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (normal saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>400mg Q2W intravenously</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Anti epidermal growth factor receptor antibody h-R3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who was confirmed stage IV esophageal carcinoma by pathologic histology or
             cytology.

          -  The sample size estimate: 20 cases per arm.

          -  Males or females aged ≥18 years, &lt; 75 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Life expectancy ≥12
             weeks.

          -  Males and females should be contraceptive during the period of the trial until 8
             weeks after the last administration of the drug.

          -  Adequate bone marrow, renal, and liver function are required.

          -  Able to comply with the required protocol and follow-up procedures, and able to
             receive oral medications.

          -  Institutional review board-approved informed consent will be obtained for every
             patient before initiation of any trial-specific procedure or treatment.

        Exclusion Criteria:

          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,
             unstable angina, congestive heart failure, myocardial infarction within the previous
             year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic
             disease).

          -  Allergy to anti-EGFR antibody.

          -  Female subjects should not be pregnant or breast-feeding.

          -  Adequate hematological function: Absolute neutrophil count (ANC) ≥1.5 x 109/L, and
             Platelet count ≥100 x 109/L. Adequate renal function: Serum creatinine ≤ 1.5 x ULN,
             or ≥ 50 ml/min. Adequate liver function: total bilirubin &lt; 1.5 x upper limit of
             normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
             &lt; 2.5 x ULN in the absence of liver metastases, or &lt; 5 x ULN in case of liver
             metastases.

          -  Patient assessed by the investigator to be unable or unwilling to comply with the
             requirements of the protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiong Zhao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiong Zhao, PhD</last_name>
    <phone>0571-87236802</phone>
    <email>doczq.2008@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first affiliated hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiong Zhao, PhD</last_name>
      <phone>0571-87236802</phone>
      <email>doczq.2008@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Qiong Zhao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qiong Zhao</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiong Zhao, PhD</last_name>
      <phone>0571-87236802</phone>
      <email>doczq.2008@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 5, 2014</lastchanged_date>
  <firstreceived_date>December 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Qiong Zhao</investigator_full_name>
    <investigator_title>Chief of Department of Thoracic Oncology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
